Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

OTL-200 em pacientes com leucodistrofia metacromática juvenil tardia (MLD)

9 de novembro de 2026 atualizado por: Orchard Therapeutics

Um ensaio aberto, não randomizado, para avaliar a segurança e a eficácia de uma única infusão de OTL-200 em pacientes com leucodistrofia metacromática (MLD) juvenil tardia (LJ).

OTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progressive demyelination affecting the central and peripheral nervous system. The aim of this clinical study is to assess the pharmacodynamic effect and long-term clinical efficacy and safety of OTL-200 in Late Juvenile MLD patients.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

6

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Milan, Itália, 20132
        • Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

All the following criteria need to be met:

  • Documented biochemical and molecular diagnosis of MLD, based on ARSA activity below the normal range and identification of two disease-causing ARSA alleles. Novel mutations will be analyzed with in silico prediction tools and excluded from being known common polymorphisms. In the case of a novel mutation(s), a 24-hour urine collection must show elevated sulfatide levels.
  • 0/R or R/R genotype or a genotype recognized as associated with the LJ variant of MLD.
  • a) If symptomatic: age at disease onset between ≥7 and <17 years of age (i.e. before their 17th birthday). OR
  • b) If pre-symptomatic: participant must be <17 years of age at treatment (i.e. before their 17th birthday) AND must have a sibling with a diagnosis of late-juvenile MLD variant based on age at disease onset (≥7 and <17 years of age i.e. before sibling's 17th birthday), with biochemical and molecular diagnosis.
  • Normal cognitive function as defined by an IQ≥85 on age appropriate cognitive scales.
  • a) If the participant is <7 years (i.e. before their 7th birthday): normal motor milestones achievement, normal gross motor function according to chronological age and normal neurological examination (if applicable based on the age of the subject, GMFC-MLD = 0) OR b) If participant is ≥7 years: normal gross motor function or mild gross motor function impairment, defined by a GMFC-MLD 0 or 1 (i.e. patient is able to walk independently).

NOTE: The following will not be exclusionary if present alone: 1.) Seizures 2.) Signs of the disease revealed at instrumental evaluations (Electroneurography [ENG] and brain MR)

  • If applicable, participant willing and capable of compliance with contraceptive use requirements.
  • Participant (or if applicable, parent/legal guardian) providing signed informed consent or assent as applicable

Exclusion Criteria:

  • Documented HIV infection (positive HIV RNA and/or anti-p24 antibodies).
  • Malignant neoplasia (except localised skin cancer) or a documented history of hereditary cancer syndrome. Participants with a prior successfully treated malignancy and a sufficient follow-up to exclude recurrence (based on oncologist opinion) can be included after discussion and approval by the Medical Monitor.
  • Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) or other serious haematological disorders.
  • Patients currently enrolled in other interventional trials
  • Has previously undergone allogeneic HSPC gene therapy (HSPC-GT) and has evidence of residual cells of donor origin.
  • Previous gene therapy.
  • Has symptomatic herpes zoster, not responsive to specific treatment. NOTE: Participants with a recent history of herpes zoster may be included in the study. In such cases, inclusion, additional monitoring and treatment of the condition must be discussed and approved by the Medical Monitor.
  • Evidence of active tuberculosis (TB) based upon medical examination, chest imaging and TB testing. Participants with latent tuberculosis, as documented by medical history and/or TB testing may be included in the study if receiving antibiotic prophylaxis (e.g. isoniazid). Inclusion, monitoring and treatment of TB in such participants must be discussed and approved by the Medical Monitor.
  • Acute or chronic stable Hepatitis B (HBV) as evidenced by positive Hepatitis B surface antigen (HBsAg) test result at screening or within 3 months prior to onset of conditioning and/or positive HBV DNA. NOTE: Participants with positive Hepatitis B core antibody due to prior resolved disease may be enrolled, only if a confirmatory negative HBsAg and negative Hepatitis B DNA test are obtained. Inclusion, monitoring and treatment of hepatitis in such participants must be discussed and approved by the Medical Monitor.
  • Presence of positive Hepatitis C RNA test result at screening. NOTE: Patients who have previously tested positive for antibodies to hepatitis C can be treated, provided they demonstrate absence of ongoing infection using a nucleic acid test with a limit of quantification of ≤15 international units/ml. Negative test results are required on at least 3 sequential occasions over a period of at least 4 weeks, after completion of treatment for Hepatitis C, with the final test conducted no more than 3 days prior to cell harvest. Inclusion, monitoring and treatment of hepatitis in such participants must be discussed and approved by the Medical Monitor.
  • End-organ dysfunction, severe active infection not responsive to treatment, or other severe disease or clinical condition which, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • In addition to the potential infections tested per protocol, the PI should consider testing for other transmissible infectious agents listed in the European Union (EU) Cell and Tissue Directive as clinically appropriate and results must be discussed with the Orchard medical monitor prior to stem cell harvest.
  • Participants with alanine transferase (ALT) >2x upper limit of normal (ULN) or total bilirubin >1.5xULN may be included only after discussed and agreed with the Orchard medical monitor and considered in the context of the criterion for excluding participants with other severe disease. Isolated elevation of total bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35% of total.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: OTL-200 Gene Therapy

OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.

All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Evaluation of OTL-200 Arylsulfatase A (ARSA) activity levels in Cerebrospinal Fluid (CSF)
Prazo: 24 months after treatment

Change from baseline in ARSA activity levels in CSF

24 months after treatment
Evaluation of OTL-200 on the neuronal metabolite ratio of N-acetyl-aspartate (NAA) to creatine (Cr) in white matter regions of the brain
Prazo: 24 months after treatment

Change from baseline in neuronal metabolite ratio of N-acetyl-aspartate (NAA) to creatine (Cr) in white matter regions of interest of the brain

24 months after treatment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in ARSA activity levels in CSF from baseline
Prazo: multiple visits up to 8 years post gene-therapy

Measured to assess the pharmacodynamic activity of OTL-200 in the Central Nervous System (CNS) post-treatment

multiple visits up to 8 years post gene-therapy
Change from baseline in neuronal metabolite ratio of NAA: Cr in white matter regions of interest of the brain
Prazo: multiple visits up to 8 years post gene-therapy

Measured to assess the pharmacodynamic activity of OTL-200 in neuronal metabolite ratio of NAA to Cr in white matter regions of interest of the brain post-treatment

multiple visits up to 8 years post gene-therapy
Change from baseline in ARSA levels in total peripheral blood mononuclear cells (PBMCs)
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

Measured to assess the pharmacodynamic activity of OTL-200 in circulating total PBMCs post-treatment

24 months and multiple visits up to 8 years post gene-therapy
Change from baseline in ARSA levels in PB CD14+
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

Measured to assess the pharmacodynamic activity of OTL-200 in circulating CD14+ post-treatment

24 months and multiple visits up to 8 years post gene-therapy
Change from baseline in ARSA levels in PB CD15+
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

Measured to assess the pharmacodynamic activity of OTL-200 in circulating CD15+ post-treatment

24 months and multiple visits up to 8 years post gene-therapy
Neuronal metabolite ratios as compared to baseline, siblings and/or untreated historical controls (may include but not limited to Cho:Cr, mIns:Cr, Lac: Cr, Cho: NAA, NAA: H2O, Cho: H2O, mIns: H2O, Lac: H2O) in white matter regions of interest
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

Measured to assess the pharmacodynamic activity of OTL-200 in neuronal metabolite ratios in white matter regions of interest of the brain post-treatment compared to siblings and/or untreated historical controls

24 months and multiple visits up to 8 years post gene-therapy
Engraftment as measured by percent lentiviral positive (%LV+) in bone marrow (BM) progenitors
Prazo: At D30 and multiple visits up to 8 years post gene-therapy

Engraftment of transduced cells will be determined by measuring the percentage of hematopoietic colony-forming cells harboring the integrated vector by quantitative polymerase chain reaction (qPCR).

At D30 and multiple visits up to 8 years post gene-therapy
Vector copy number (VCN) in BM mononuclear cells
Prazo: At D30 and multiple visits up to 8 years post gene-therapy

Engraftment of transduced cells will be determined by measuring the VCN per genome in BM-derived cells.

At D30 and multiple visits up to 8 years post gene-therapy
VCN in Peripheral blood PBMCs
Prazo: At D60 and multiple visits up to 8 years post gene-therapy

Engraftment of transduced cells will be determined by measuring the VCN per genome in PBMCs.

At D60 and multiple visits up to 8 years post gene-therapy
Change in severity scale for brain magnetic resonance imaging (MRI)
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

Brain MRI will be assessed using modified Loes Score and demyelination load on T1w, T2w and FLAIR imaging.

24 months and multiple visits up to 8 years post gene-therapy
Change in neurocognitive function
Prazo: 24 months and multiple visits up to 8 years post gene-therapy as compared to baseline

Neurocognitive assessments will use Bayley Scale of Infant and Toddler Development (BSID), Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Wechsler Intelligence Scale for Children (WISC), or Wechsler Adult Intelligence Scale (WAIS) according to the age of the participant to encompass performance, verbal, full scale IQ measures, processing speed and working memory indices

24 months and multiple visits up to 8 years post gene-therapy as compared to baseline
Change in full neurological clinical examination (NCE)
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

Neurological examinations will be performed to evaluate the effect of OTL-200 on the onset or progression of MLD disease.

24 months and multiple visits up to 8 years post gene-therapy
Change in Gross Motor Function Classification (GMFC)-MLD
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

GMFC-MLD will evaluate the change in motor function according to seven clinically relevant levels of walking, sitting, locomotion, trunk and head control. The scoring range is from 0 (walking without support with quality of performance normal for age) to 6 (loss of any locomotion as well as loss of any head and trunk control).

24 months and multiple visits up to 8 years post gene-therapy
Change in NCV
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

NCV will be assessed by electroneurography which is a technique used to test and quantify the nerve conduction and impulse propagation along motor and sensory peripheral nerves.

24 months and multiple visits up to 8 years post gene-therapy
Vineland Adaptive Behavior Scale (VABS)
Prazo: 24 months and multiple visits up to 8 years post gene-therapy

VABS will assess the individual's ability to undertake daily activities appropriate for their age group.

24 months and multiple visits up to 8 years post gene-therapy
Conditioning regimen related toxicity and AEs
Prazo: up to 8 years post gene-therapy

To evaluate the safety and tolerability of the HSPC GT procedure.

up to 8 years post gene-therapy
Non-conditioning related AEs
Prazo: up to 8 years post gene-therapy

To evaluate the safety and tolerability of OTL-200.

up to 8 years post gene-therapy
Hematological reconstitution
Prazo: By Day 60 post-gene therapy

Hematological reconstitution defined as absolute neutrophil count [ANC] ≥ 500/µL and platelet count ≥20,000 platelets/μL with associated evidence of BM recovery

By Day 60 post-gene therapy
Incidence of infusion related reactions
Prazo: up to 8 years post gene-therapy

To evaluate the safety and tolerability of the HSPC GT procedure.

up to 8 years post gene-therapy
Immune response (e.g. anti-ARSA antibodies)
Prazo: up to 8 years post gene-therapy

Plasma samples will be collected for anti-ARSA antibody analysis

up to 8 years post gene-therapy
Abnormal Clonal Proliferation (ACP)
Prazo: up to 8 years post gene-therapy

Malignancy or ACP due to insertional oncogenesis will be evaluated using different tests and procedures.

up to 8 years post gene-therapy
Replication Competent Lentivirus (RCL
Prazo: baseline, 1, 3, 6, and 12 months, then once a year up to 8 years post gene-therapy

Molecular monitoring of RCL will be assessed via enzyme-linked immunosorbent assay (ELISA) test for serum human immunodeficiency virus (HIV) p24 antigen. A positive HIV p24 test result is subject to second level testing including: a) DNA PCR for vesicular stomatitis virus G (VSV-G) envelope (PBMC), and b) reverse transcription (RT)-PCR for serum HIV-pol ribonucleic acid (RNA) (plasma).

baseline, 1, 3, 6, and 12 months, then once a year up to 8 years post gene-therapy
Integration Site analysis findings
Prazo: 6, 12 months, then once a year up to 8 years post gene-therapy

Detailed analysis of LV integrations will be performed on PB and BM cells, to monitor the nature and distribution of Integration Sites

6, 12 months, then once a year up to 8 years post gene-therapy

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Orchard Clinical Trials, Orchard Therapeutics

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de janeiro de 2022

Conclusão Primária (Real)

15 de janeiro de 2026

Conclusão do estudo (Estimado)

30 de abril de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

13 de fevereiro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de fevereiro de 2020

Primeira postagem (Real)

25 de fevereiro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever